EGFR and mucositis: However, the AEs spectrum of the anti-EGFR and paclitaxel combination is not comparable to that for TPF as grade 3–4 AEs mainly involved skin toxicity and mucositis and only led to treatment discontinuation in 11.8% of patients (9).